Related Experiment Videos
Perioperative approaches to coagulation defects
1Cardiac Surgical Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, England.
Insights
Aprotinin, a serine protease inhibitor, effectively reduces bleeding and transfusion needs in cardiac surgery patients. This blood conservation strategy is crucial for minimizing complications associated with cardiac operations.
Area of Science:
- Cardiology
- Anesthesiology
- Hematology
Background:
- Cardiac surgery often leads to bleeding complications and hemostatic defects.
- Blood transfusions carry risks, making blood conservation a priority.
- Patient-specific factors and surgical procedures can induce hemostatic issues.
Purpose of the Study:
- To evaluate therapeutic approaches for managing bleeding in cardiac surgery.
- To highlight the efficacy of aprotinin in reducing blood loss and transfusion requirements.
- To discuss clinical use, dosage, and risk-benefit balance of aprotinin therapy.
Main Methods:
- Review of therapeutic strategies including autotransfusion and pharmacotherapy.
- Analysis of clinical data on aprotinin use in cardiac surgery patients.
- Discussion of dosage regimens and monitoring of automated clotting time.
Main Results:
- Aprotinin demonstrated significant and consistent efficacy in reducing bleeding.
- Aprotinin therapy substantially decreased the need for blood and blood product transfusions.
- High-risk patients particularly benefited from aprotinin's hemostatic effects.
Conclusions:
- Aprotinin is a highly effective drug for managing bleeding in cardiac surgery.
- Its use contributes to blood conservation and reduces transfusion-related risks.
- Careful consideration of indications and risk-benefit is essential for aprotinin therapy.
Abstract:
Cardiac surgical procedures are known to be associated with coagulation defects and disordered hemostasis. Excessive perioperative and postoperative bleeding and the need for considerable volumes of blood and blood product transfusions are well recognized. The risks of blood transfusion with high donor-exposure levels have focused attention on blood conservation as a priority in reducing the complications of cardiac operations. Hemostatic defects may be related to patient-inherent coagulopathies, preexisting associated pathology, and preoperative drug therapy. In addition, hemostatic defects are induced during the operation itself. Two principal therapeutic approaches to this complex problem have evolved. Although different, these approaches are not mutually exclusive and may be used complementarily. The first is autotransfusion and the second is hemostatic drug therapy. Although many drugs have been tried, including antifibrinolytic agents (epsilon-aminocaproic acid, tranexamic acid), platelet-preserving agents (prostacyclin, dipyridamole), and desmopressin, the only drug that has shown significant and consistent efficacy in reducing bleeding in cardiac surgery patients is the serine protease inhibitor aprotinin. Aprotinin has been shown to be highly effective in reducing blood loss and blood and blood product transfusion requirements in high-risk patients. Clinical experience with aprotinin therapy in cardiac patients and specific issues such as dosage regimens and the target automated clotting time levels in patients on high-dose aprotinin therapy are outlined. Indications for the use of aprotinin and the balance between risk and benefit are discussed.